Pluri is a bio-technology company focused on the field of regenerative medicine. Co. is developing placenta-based cell therapy product candidates for the treatment of muscle trauma, hematological disorders, radiation damage and inflammation. Co.'s operations are focused on the research, development and manufacturing of cells, conducting clinical studies and the business development of cell therapeutics and cell based technologies, such as its collaboration with Tnuva Food Industries – Agricultural Cooperative in Israel Ltd.,through its fully owned subsidiary, Tnuva Food-Tech Incubator (2019), Limited Partnership, to use Co.'s technology to establish a cultured food platform. We show 4 historical shares outstanding datapoints in our coverage of PLUR's shares outstanding history.
Understanding the changing numbers of PLUR shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like PLUR versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching PLUR by allowing them to research PLUR shares outstanding history
as well as any other stock in our coverage universe. |
Free PLUR Email Alerts:
Video: Shares Outstanding Importance
